- Celanese Corp CE has received a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant.
- CE expects the project to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
- Through this grant, Celanese will provide critical research and development activities to facilitate and accelerate access to long-acting contraceptive options.
- "The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe," commented Laura Brand, VP of the Celanese medical and pharmaceutical business.
- Price Action: CE shares are trading lower by 0.04% at $115.95 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
